Sputnik V Vaccine: India to Produce 300mn Doses Of Vaccine in 2021

In 2021, India will produce about 300 million doses of the Russian Sputnik V coronavirus vaccine.

In 2021, India will produce about 300 million doses of the Russian Sputnik V coronavirus vaccine, said the head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev.

"In India, we have agreements with four large manufacturers. ...India will produce about 300 million doses or more of the vaccine for us next year," he was quoted as saying to Rossiya 24 TV channel by TASS news agency on Thursday.

Side Effects, Efficacy Reasons for COVID Vaccine Hesitancy in India: Study
Even as the Central government preps up to roll out the COVID-19 vaccination drive soon, about 60 percent of people are hesitant to take it due to the fear of side effects, efficacy, and reduction in cases, according to a new study.

‘The Russian Sputnik V will be actively produced in the world and we see that this is built on a safe platform based on the human adenovirus.’

RDIF is Russia's sovereign wealth fund.

Dmitriev noted that out of 110 production sites that negotiated production of Sputnik V, RDIF chose 10 that meet its requirements.

Earlier Dmitriev said that production of Sputnik V began in other countries, in particular in India, Korea, Brazil, and China.

Around 53 Percent Indians Express Concern Over Taking COVID Vaccine: Survey
While the Central Government has geared up for the vaccination drive, over 50 percent of India's population has expressed caution towards taking the COVID-19 vaccine, a survey revealed.

Registered by Russia on August 11, Sputnik V became the world's first coronavirus vaccine.

The vaccine was developed by the Gamaleya National Research Center of Epidemiology and Microbiology.

Nearly 21 Percent US Adults Not Planning to Get Covid Vaccine: Survey
As the US prepares its nationwide vaccination program, a new survey has revealed that at least 21.3 percent of adults in the country are not planning to get the coronavirus vaccine shot.

Its post-registration trials began in Moscow on September 7, with volunteers receiving the first vaccine on September 9.

A total of 40,000 people are involved in the programme.

COVID Vaccine: Moderna Coronavirus Vaccine All Set For FDA Emergency Approval
A high powered vaccine advisory panel has endorsed Moderna's COVID-19 vaccine for emergency use approval (EUA) by the FDA.

RDIF supports the development of Russia's Covid-19 vaccine by the Gamaleya Center and is investing in mass production of the vaccine by RDIF portfolio companies.

Source-IANS